SMAD3 and heart failure: The effect of EGCG against heart failure was diminished on treatment with TGF‐β1 inhibitor, showing that EGCG inhibited the progression and development of heart failure in mice via inhibition of myocardial fibrosis and decrease of ventricular collagen remodeling, through inhibition of TGF‐β1/smad3 signaling pathway [60].